96PD - Clinical activity, safety and subpopulation response analysis of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pt) with non-small cell lu...
|Date||28 March 2014|
|Session||Poster Discussion 2|
|Topics|| Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
J.R. Brahmer1, L. Horn2, S.J. Antonia3, D.R. Spigel4, L.V. Sequist5, C.M. Ahlers6, V. Sankar6, G. Kollia6, S. Gettinger7
Treatment with nivolumab, a fully human IgG4, PD-1 immune checkpoint inhibitor antibody resulted in durable objective responses (ORs) and prolonged stable disease in pts with advanced NSCLC in a phase 1 study (CA209-003; NCT00730639) (Topalian S, et al. N Engl J Med. 2012;366:2443-54). We report long-term safety, efficacy, updated survival outcomes and clinical activity in subpopulations of the NSCLC cohort.